Statistical Challenges in the Evaluation of Treatments for Small Patient Populations
暂无分享,去创建一个
[1] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[2] David L. DeMets,et al. Data Monitoring Committees in Clinical Trials: A Practical Perspective , 2002 .
[3] T. Brennan,et al. The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer. , 2001, Health affairs.
[4] Hanmin Lee,et al. A randomized trial of fetal endoscopic tracheal occlusion for severe fetal congenital diaphragmatic hernia. , 2003, The New England journal of medicine.
[5] Murray K. Clayton,et al. BAYES DISCRETE SEQUENTIAL BOUNDARIES FOR CLINICAL TRIALS , 2001 .
[6] Matthias Griese,et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.
[7] H. Brachinger,et al. Decision analysis , 1997 .
[8] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[9] A. Griffiths,et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. , 2007, Gastroenterology.
[10] P. Armitage. Sequential Medical Trials , 1961, Biomedicine / [publiee pour l'A.A.I.C.I.G.].
[11] J. Abrams,et al. Much ado about not...enough data: high-dose chemotherapy with autologous stem cell rescue for breast cancer. , 1998, Journal of the National Cancer Institute.
[12] G. Hortobagyi. What is the role of high-dose chemotherapy in the era of targeted therapies? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Daniel,et al. There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. , 1998 .
[14] J. Blay,et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. , 2005, European journal of cancer.
[15] J. Hampe,et al. Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease , 1999, The Lancet.
[16] A R Feinstein,et al. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.
[17] G. Ginsburg,et al. The path to personalized medicine. , 2002, Current opinion in chemical biology.
[18] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[19] S. Sicherer,et al. Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition , 2007, Pediatrics.
[20] A. Giobbie-Hurder,et al. Disease Progression in Hutchinson-Gilford Progeria Syndrome: Impact on Growth and Development , 2007, Pediatrics.
[21] B. Freidlin,et al. Outcome--adaptive randomization: is it useful? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[23] Boris Freidlin,et al. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Boris Freidlin,et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] R. Simon,et al. Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] B. Freidlin,et al. Monitoring for lack of benefit: a critical component of a randomized clinical trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] H L Greene,et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.
[28] D. Alling,et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. , 1972, The New England journal of medicine.
[29] Paul S Albert,et al. Assessing surrogates as trial endpoints using mixed models , 2005, Statistics in medicine.
[30] J P Miller,et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. , 1984, Circulation.
[31] N. Barth,et al. High-dose chemotherapy with autologous stem cell rescue in breast cancer , 2005, Breast Cancer Research and Treatment.
[32] J. Ruskin,et al. The cardiac arrhythmia suppression trial (CAST). , 1989, The New England journal of medicine.
[33] R. Gray,et al. Multi-Arm Clinical Trials of New Agents: Some Design Considerations , 2008, Clinical Cancer Research.
[34] Lisa M. McShane,et al. Effective Incorporation of Biomarkers into Phase II Trials , 2009, Clinical Cancer Research.
[35] A. Fischer,et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. , 2002, American journal of human genetics.
[36] J A Smyth,et al. Determining optimal therapy--randomized trials in individual patients. , 1986, The New England journal of medicine.
[37] M J Daniels,et al. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta‐analysis of studies of the AIDS Clinical Trials Group , 1998, AIDS.
[38] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[39] R. Demasi,et al. Meta-Analysis of Antiretroviral Effects on HIV-1 RNA, CD4 Cell Count and Progression to AIDS or Death , 1998, Antiviral therapy.
[40] T. Johannessen,et al. Controlled trials in single subjects. 1. Value in clinical medicine. , 1991, BMJ.
[41] N. Heerema,et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Boris Freidlin,et al. Conditional power calculations for clinical trials with historical controls , 2006, Statistics in medicine.
[43] Mark Rothmann,et al. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[45] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[46] A. Giobbie-Hurder,et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome , 2012, Proceedings of the National Academy of Sciences.
[47] Boris Freidlin,et al. Reply to Y. Yuan et al , 2011 .
[48] P. Armitage,et al. Repeated Significance Tests on Accumulating Data , 1969 .
[49] Robert H. Bartlett,et al. Berlin Heart EXCOR Pediatric ventricular assist device Investigational Device Exemption study: study design and rationale. , 2011, American heart journal.
[50] Boris Freidlin,et al. Design issues in randomized phase II/III trials. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] Rossella Bertulli,et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.
[52] Eugene H Blackstone,et al. Prospective trial of a pediatric ventricular assist device. , 2012, The New England journal of medicine.
[53] S. Senn. Controlled trials in single subjects. , 1991, BMJ.
[54] D. Alling,et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.
[55] R. Gray,et al. A general inefficacy interim monitoring rule for randomized clinical trials , 2010, Clinical trials.
[56] Max Halperin,et al. An Adaptive Procedure for Sequential Clinical Trials , 1969 .
[57] Boris Freidlin,et al. Adaptive randomization versus interim monitoring. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] B. Freidlin,et al. Data monitoring committees and interim monitoring guidelines. , 1999, Controlled clinical trials.
[59] K. K. Lan,et al. Discrete sequential boundaries for clinical trials , 1983 .
[60] G. Graff,et al. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study. , 2010, Clinical therapeutics.
[61] H L Greene,et al. The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. , 1992, Journal of the American College of Cardiology.
[62] D. Alling,et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.
[63] D. Sargent,et al. Survival is not a good outcome for randomized trials with effective subsequent therapies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] G. W. Snedecor. STATISTICAL METHODS , 1967 .
[65] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.
[66] S. Holland,et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. , 2006, The New England journal of medicine.
[67] S S Ellenberg,et al. An efficient design for phase III studies of combination chemotherapies. , 1985, Cancer treatment reports.
[68] Stephen W Lagakos,et al. Testing and interval estimation for two-sample survival comparisons with small sample sizes and unequal censoring. , 2010, Biostatistics.
[69] E. Remmers,et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. , 2002, Arthritis and rheumatism.
[70] W. Silverman,et al. The influence of the thermal environment upon the survival of newly born premature infants. , 1958, Pediatrics.
[71] Controlled trials in single subjects. 2. Limitations of use. , 1991, BMJ.
[72] E Blacker. Some design considerations , 1960 .
[73] J. Clancy,et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. , 2010, The New England journal of medicine.
[74] B. Wilcken. Rare diseases and the assessment of intervention: What sorts of clinical trials can we use? , 2001, Journal of Inherited Metabolic Disease.
[75] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[76] E. Korn,et al. Choice of column scores for testing independence in ordered 2 X K contingency tables. , 1987, Biometrics.
[77] P. Adamson,et al. New approaches to drug development in pediatric oncology. , 2005, Cancer journal.
[78] S. Paul,et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. , 2012, Arthritis and rheumatism.
[79] Ying Yuan,et al. On the usefulness of outcome-adaptive randomization. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] Daniel J Sargent,et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] A. Jaffe,et al. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. , 1984, The American journal of cardiology.
[82] J. O'fallon,et al. Stopping when the experimental regimen does not appear to help. , 1994, Statistics in medicine.
[83] Laurence L. George,et al. The Statistical Analysis of Failure Time Data , 2003, Technometrics.
[84] D. Berry,et al. Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. , 1995, Statistics in medicine.
[85] R. D. Boschloo. Raised conditional level of significance for the 2 × 2‐table when testing the equality of two probabilities , 1970 .